Boehringer Ingelheim Expressed “Confidence in the Future” With Recording Positive Momentum in 2020 and Expanding R&D Investment
On the afternoon of the 24th, Boehringer Ingelheim held an online annual press conference and announced the progress of its 2020 annual results and business plans. The event was attended by Hubertus von Baumbach, Chairman of the Board of Managing Directors, and Michael Schmelmer, the Member of the Board of Managing Directors responsible for Finance and Group Functions.Currently, Boehringer Ingelheim is engaged in several projects aimed at finding medical solutions to treat COVID-19. In December 2020, the company announced together with Cologne University Hospital, the University of Marburg, and the German Center for Infection Research the initiation of Phase I/IIa clinical investigation of BI 767551. BI 767551 is the first SARS-CoV-2 neutralizing antibody administrated via inhalation as a potential new therapeutic and prophylactic option to block the virus at the site of infection. Other COVID-19 initiatives include the research and development of SARS-CoV-2 antibodies that can be combined with BI 767551, small molecules to inhibit its replication, and therapy development to prevent microcoagulation. ▲ Hubertus von Baumbach, Chairman of the Board of Managing Directors of Boehringer Ingelheim Hubertus von Baumbach stated that last year Boehringer Ingelheim drastically expanded its R&D investment by promoting the development of innovative medicines and treatments for diseases that do not yet have enough cures. In particular, the company accelerated efforts to research candidates for treatments related to COVID-19, and the total annual R&D investment in 2020 was 3.7 billion EUR, an increase of 7% from the previous year, the highest amount ever in the history of Boehringer Ingelheim for 136 years. Baumbach expressed his ambition, "2020 was a year that reaffirmed Boehringer Ingelheim's long-term R&D vision, and we try to move forward with greater confidence in the future."“The COVID-19 pandemic became an opportunity to find out what direction science is developing and how to contribute, and which field opportunities can be seized rather than risks. Recognizing the urgency of response to COVID-19, we started R&D on therapeutic candidates from the beginning of the first quarter of 2020. Research is underway with several partners around the world for patients,” Baumbach said. “Boehringer Ingelheim's executives and employees have continued to provide medicines and support medical staff to patients and animals. The achievements in 2020 are the result of our employees' efforts.”Besides, Baumbach emphasized the importance of partnership. “Looking back in 2020, Boehringer Ingelheim cannot help appreciating the support received from our partners. Funds and supplies have been provided in many countries around the world, helping COVID-19 patients and communities quickly and efficiently.” Also, “The recent partnership agreement between Boehringer Ingelheim and Google Quantum AI will be an opportunity to bring together all the necessary resources by combining our medical expertise with the algorithms of Google Quantum Computer.”Meanwhile, the Animal Health business of Boehringer Ingelheim is one of the largest providers of veterinary vaccines and medicines and has a strong presence in the livestock and companion animal segments. In 2020, the Animal Health business delivered a strong performance in a highly competitive market and grew by 5%, with net sales of 4.12 billion EUR. Baumbach explained, “Since Boehringer Ingelheim made a strategic decision to pay more attention to the field of animal health and veterinary medicine in 2016, we have continuously strived to develop synergies based on our knowledge between human and veterinary medicines.” ▲ Michael Schmelmer, the Member of the Board of Managing Directors responsible for Finance and Group Functions of Boehringer Ingelheim Michael Schmelmer gave a detailed introduction to Boehringer Ingelheim's performance in 2020, as well as business status including M&A and R&D. “2020 was a good year for Boehringer Ingelheim, although the effects of the COVID-19 pandemic were omnipresent. All of its businesses contributed positively to net sales and operating income. The company recorded net sales of 19.57 billion EUR, a 3% increase compared to the previous year. Foreign currency headwinds had a considerable impact; adjusted for currency effects, net sales rose by 5.6% year on year,” Schmelmer said. Also, “We met our ambitious targets, both in terms of our contribution to the wellbeing of humans, pets and livestock, and our business performance. This allows us to continue to invest even more in R&D, as well as in the long-term opportunities we have identified, most notably in the fields of oncology as well as digital and data technologies.”According to the presentation, operating income at the Group level rose to 4.62 billion EUR. One-time gains from divestitures supported the operating income. Income after taxes saw a 12.5% year-on-year increase to 3.06 billion EUR. Cash flow from operating activities increased by 619 million EUR to 3.96 billion EUR. At the end of 2020, the equity ratio stood at 47%. Moreover, the company invested 1.05 billion EUR in tangible assets in 2020, including the large-scale production facility for biopharmaceutical products (LSCC) in Vienna, Austria, and the new development center for biopharmaceutical medicines (BDC) in Biberach, Germany.Last year, Boehringer Ingelheim conducted several M&As to expand its portfolio through selection and concentration. In July, the company announced the acquisition of Global Stem cell Technology (GST), a Belgian veterinary biotech company, to develop and produce state-of-the-art stem cell products for horses and pets. In September, an equity stake in the China-based New Ruipeng Group, a company that specializes in providing medical care services for pets, was acquired. In December, the company announced the acquisition of all shares of NBE-Therapeutics, a clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune-stimulatory iADC™ platform.Wrapping up the presentation, Schmelmer revealed the outlook for 2021. “2021 will be a year in which we continue to cope with the challenges posed by COVID-19. The difficult industry environment caused by increasing price pressures in several major markets is expected to affect 2021 earnings. Assuming that the approved vaccines and other medicines currently undergoing the approval process help curb the COVID-19 pandemic, the company expects strong general market growth for prescription pharmaceuticals. For 2021, Boehringer Ingelheim expects to achieve a slight year-on-year increase in net sales on a comparable basis.”
Hyperconnect, Key to social platform success: reflecting the ‘user voice’
- From tailored engagement features to high standards of community safety — proactively reflecting the needs of “MZ” generation users Social platforms that are popular among the so-called “MZ” generations (Millennials and Generation Z combined) seem to share a common practice: they listen to their users and structure products according to direct feedback. As the protagonists in a new digital era, MZ users are shaping social services through their demands for live, interactive content against a safe and friendly community backdrop. ■ Hakuna Live enables diverse experiences and ensures safe communities Hakuna Live, the second hit project launched by Seoul-based video and AI technology company Hyperconnect, takes the traditional live streaming concept — where one “mega host” broadcasts to many — and enhances it via multi-way communication modes. Dubbed ‘social live streaming’, Hakuna helps every user find his or her place in the social universe — from light chat to counseling, quiz shows, rap battles, casual games and more. As entertainment consumption continues its shift online in the era of COVID-19, Hakuna Live is rapidly growing by introducing MZ-targeted features. For example, Hakuna’s “Guest Mode” allows up to four to co-broadcast simultaneously through a split screen layout, enabling a diverse playground-like experience; Augmented Reality (AR) Avatar mode allows streamers and guests to express themselves with fun, facial data-based characters. This year, Hakuna expects to expand upon its Guest Mode with “Group Chat Live’, allowing up to six people to chat together, further blurring the traditional lines between entertainer and entertained Critically, Hakuna Live is acutely focused on maintaining a safe online community and has spared no expense in building advanced artificial intelligence-powered monitoring systems that can automatically detect and report and variety of unwanted content. Hyperconnect also assembled a Community Safety Supervision Committee in November 2020, consisting of former partners from reputable law firms and former judges. Hakuna Live is currently serviced in 10 countries — including Japan, Turkey, India, North America, and Taiwan — and is planning to expand its MZ-focused launch even further this year. ■ After the success of ‘Snow', Naver’s ‘ZEPETO’ gains ground through a user-first focus The augmented reality avatar platform ZEPETO, operated by Naver Z, now counts over 180 million amongst its global subscriber base — in just two years after its launch. ZEPETO is a product squarely aimed at the MZ users with its 3D avatar environment that uses the latest in facial recognition and AR technology. ZEPETO has also actively catered towards MZ users through its partnerships with generation-relevant content, reportedly earning over 12 billion won from its partnership with Big Hit Entertainment and YG Entertainment and 5 billion won from its partnership with JYP. ZEPETO’s success follows the positive feedback that the Naver-owned ‘Snow’ received from users after adding augmented reality capabilities to its camera app. ■ Facebook’s shift towards “followers” over “likes” To keep up with the needs and feedback of its younger users, Facebook too recently announced plans for a meaningful overhaul to its platform. For example, on pages used by public figures, the 'Like' function — which has been the target of much negative press — has been dropped in favor of focusing on 'follower' count. This change, which positions Facebook as something closer to YouTube and Instagram, is intended give creators a firmer indication of their fan base Facebook had reportedly tested the deletion of ‘Like’ in a number of markets and ultimately made the determination based on user feedback. Facebook will also introduce a dedicated news feed and Q&A function for active exchanges between friends, colleagues, and fans — a step towards deepening “communication” between users, which is highly valued by MZ generations.
Hyperconnect : real-time video AI monitoring system can now auto-block live video content within 0.006 seconds
- Serverless “on-device” artificial intelligence technology pre-filters content at lightning-fast-speeds - Substantial continued investment in user community health and safety According to a representative from Hyperconnect, a recent update enables the company’s real-time video artificial intelligence (AI) monitoring system to pre-block and filter content within 0.006 seconds. Hyperconnect, the Seoul-based AI and video technology company behind Azar and Hakuna Live, has been focused on developing deep learning-based AI monitoring systems for several years. Hyperconnect developed the initial iteration of its AI monitoring system in 2017 — a global-first system capable of filtering content in a live video environment without data ever hitting the server. Dubbed “on-device artificial intelligence”, Hyperconnect’s AI engine drives powerful in-app capabilities directly on a user's device where the app is installed. Since live video can be monitored — and users protected — without data leaving the device, user privacy is preserved. Since then, Hyperconnect has continued to invest aggressively in improving monitoring performance. Depending on mobile device specification, in less than one-tenth of one second — as fast as 0.004 seconds on an iPhone XR and 0.006 seconds for Galaxy S10 devices — content that violates user guidelines in can be automatically concealed from other users. "We have reinforced user protection with the world's best AI monitoring technology, which, along with hundreds of monitoring personnel, is able to block inappropriate content in 0.006 seconds or less for Galaxy S10 users," according to HyunTaek “Eddie” Yong, Hyperconnect's Chief Technology Officer. “Hyperconnect will continue to channel company-wide resources into the development of technologies and best practices that protect users and create healthy user environments.” Recently, Hyperconnect’s AI monitoring system was deployed to its newest social app products: Slide, a social discovery dating app launched in the North American and German markets, and 'Hakuna Live', a social live streaming service available in several markets globally. Hyperconnect’s advanced monitoring technology will also be packaged into the upcoming SDK from Hyperconnect Enterprise, enabling corporate clients globally to create safe and fun environments within various types of live, video services.
Coupang key officers rang the opening bell of the NYSE(New York Stock Exchange)
Coupang rang the opening bell of the New York Stock Exchange(NYSE). At 9:30 a.m. on the 11th, Coupang announced its debut on 'Big Board' with ringing the opening bell to inform of opening. The NYSE is the world's largest stock exchange and is also called the “Big Board”. The opening bell ceremony was held to celebrate Coupang's listing on the NYSE and commemorate its first step in the global financial market. The company's key officers, including Kim Beom-seok, chairman of Coupang's board of directors, CEO Kang Han-seung and Park Dae-joon, and CFO Gerab Anand, attended the ceremony. Those who have been with Coupang's challenge and growth, such as customers, delivery staff, and open market sellers, made the opening bell ceremony more meaningful by joining through the online screen. "We are pleased to put the name of 'Coupang' on Wall Street, the world's financial center. As our competitiveness has been recognized on the global stage, we will use this opportunity as a stepping stone and continue to take on even greater challenges," an officer from Coupang claimed.
Osaka Gas Co., Ltd. and Sojitz Corporation: Fuel Switching Business at Food Plants in Vietnam
– Switching From Coal to Natural Gas to Reduce CO2 Emissions by Approx. 76,300t Over 10 Years – OSAKA, Japan--(BUSINESS WIRE)--Sojitz Corporation (President: Masayoshi Fujimoto; “Sojitz”) and Osaka Gas Co., Ltd.’s (President: Masataka Fujiwara; “Osaka Gas”) joint venture company*¹ Sojitz Osaka Gas Energy Company Ltd. (General Director: Yoshiro Aoyama; “SOGEC”) has concluded a supply agreement on March 4th, 2021 with Acecook Co., Ltd.’s (“ACJ”) subsidiary, Acecook Vietnam Joint Stock Company (“ACV”), to provide natural gas to ACV’s food plants. SOGEC is concentrating its efforts on fuel switching from coal to natural gas, and this project marks the company’s first time supplying natural gas to an individual business.*² This natural gas supply business will be a subsidized project*³ under Japan’s Joint Crediting Mechanism (JCM)*⁴ scheme. Additionally, this project will be undertaken in cooperation with the governments of Vietnam and Japan. In partnership with Osaka and Ho Chi Minh City, ACV and SOGEC participated in a feasibility study*⁵ for reducing CO2 in food plants prior to replacing the coal-fired steam boilers at two of ACV’s plants with highly-efficient gas-fired steam boilers that use natural gas with the objective of improving the plants’ work environment and reducing CO2 emissions. This business expects to reduce CO2 emissions by approximately 76,300t over a 10-year period. Under the JCM scheme, over half of this reduced CO2 amount will be issued as JCM carbon credits and delivered to the Japanese government, which will help Japan to realize its reduction targets for CO2 emissions. Sojitz, Daigas Group (an Osaka Gas group brand), and SOGEC will continue to respond to the diverse business needs of its customers through the sale of environmentally-friendly natural gas, contributing to Vietnam’s sustainable development and to the realization of a low-carbon society. *1: Equity ownership of Sojitz Osaka Gas Energy Company Ltd.: Sojitz Group 51%, Osaka Gas Singapore Pte. Ltd. 49%. (Osaka Gas Singapore Pte. Ltd. is a fully-owned subsidiary of Osaka Gas Co., Ltd.) *2: In April 2020, SOGEC began supplying natural gas to Phu My 3 Specialized Industrial Park in Bà Rịa-Vũng Tàu Province in Southern Vietnam. *3: Financing Programme for JCM Model Projects in FY2020 JCM Model Projects utilize leading low-carbon and decarbonization technologies to lower GHG emissions in developing countries through measurable, reportable, and verifiable (MRV) actions. In addition to reducing GHG emissions in developing countries, JCM projects aim to help Japan and its partner countries achieve their GHG emission reduction targets. The Financing Progarmme for JCM Model Projects will fund up to half of the initial investment costs for advanced low-carbon and decarbonization technologies. The Global Environment Centre Foundation (GEC) has been commissioned by the Ministry of the Environment of Japan (MOEJ) to function as a secretariat to manage JCM-related subsidy programs, which are open to private enterprises in Japan. ACJ, ACV and SOGEC received financing from MOEJ under the Financing Programme for JCM Model Projects in FY2020 on September 28th, 2020. *4: Joint Crediting Mechanism (JCM): In this bilateral mechanism, Japan provides developing countries with leading low-carbon technologies and products, systems, services, and infrastructures, which contribute to sustainable development in these countries by reducing greenhouse gas emissions. With JCM projects, both countries are able to benefit from reduced emissions. Japan’s efforts to reduce greenhouse gas emissions can be evaluated quantitatively through JCMs, which allow Japan to apply JCM credits to meet its emission reduction targets. *5: As part of the City-to-city Collaboration Programme, this feasibility study was commissioned by the Ministry of the Environment of Japan (MOEJ) to support effective and efficient initiatives for building low-carbon and decarbonized society models, which are undertaken by Japanese municipalities with expertise on constructing these models and partner cities outside Japan. Osaka and Ho Chi Minh City jointly took part in this City-to-City Cooperation Project in which ACV and SOGEC also participated. （Attachment） 1. Project Overview Equipment to be Installed Steam Supply Capacity 7,000 kg/h per unit (converted evaporation amount) Installed Units 13 units (2 plants) Supplied Fuel Natural gas and LPG-air Estimated Reduction of CO2 7,631t- CO2 /year Start Date July 2021 (planned) Location and Exterior (Façade) of Installation Sites - ACV Hung Yen plant Nhu Quynh Town, Van Lam District, Hung Yen Province - ACV Binh Duong plant Quarter 1B, An Phu Ward, Thuan An Town, Binh Duong Province 2. Participating Companies [Company Overview – Sojitz Osaka Gas Energy Company Ltd.] Established October 2019 Location Ba Ria - Vung Tau Province, Socialist Republic of Vietnam Representative Director Yoshiro Aoyama Ownership Sojitz Group - 51% (Sojitz Corporation - 26%, Sojitz Vietnam Co., Ltd. - 25%） Osaka Gas Singapore Pte. Ltd. - 49% Main Business Supply of natural gas to industrial users, energy services, and energy-related engineer and consulting services in Vietnam [Company Overview – Sojitz Corporation] Established April 2003 Location 1-1, Uchisaiwaicho 2-chome, Chiyoda-ku, Tokyo Representative Director Masayoshi Fujimoto Main Business General trading company (trading and business investment in Japan and overseas) [Company Overview – Osaka Gas Co., Ltd.] Established April 1897 Location 4-1-2 Hiranomachi, Chuo-ku, Osaka Representative Director Masataka Fujiwara Main Business Gas production, supply, and sales; power generation, supply, and sales 3. Related News Releases Sojitz Corporation: “Sojitz and Osaka Gas Establish Natural Gas Supply Company in Vietnam” (Jun. 24th, 2019) https://www.sojitz.com/en/news/2019/06/20190624.php Osaka Gas Co., Ltd.: “Establishing a Natural Gas Supply Company in Vietnam” (Jun. 24th, 2019) https://www.osakagas.co.jp/en/whatsnew/__icsFiles/afieldfile/2019/06/24/190624_2_1.pdf Contacts Press Inquiries: Osaka Gas Co., Ltd. International Business Strategy Team Strategy & Planning Dept. Energy Solution Business Unit Tel: +81-(0)6-6205-3546 Sojitz Corporation Public Relations Dept. Tel: +81-(0)3-6871-3404
Ancora Files Definitive Proxy Statement and Sends Letter to Blucora Stockholders
Contends Stockholder-Driven Change is Urgently Needed in Blucora’s Boardroom After Years of Poor Governance and Strategic Missteps, Which Have Destroyed Significant Value and Undermined the Company’s Long-Term Viability Urges Stockholders to Vote on the WHITE Proxy Card to Elect Ancora’s Four Highly-Qualified Director Candidates, Who Each Possess Deep Industry Experience and Independent Perspectives CLEVELAND--(BUSINESS WIRE)--Ancora Holdings, Inc. (together with its affiliates, “Ancora”), which collectively with the other participants in its solicitation beneficially owns approximately 3.4% of the outstanding common stock of Blucora, Inc. (“Blucora” or the “Company”) (NASDAQ: BCOR), today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission and sent a letter to the Company’s stockholders. Ancora has nominated four highly-qualified candidates for election to Blucora’s Board of Directors (the “Board”) at the Company’s 2021 Annual Meeting of Stockholders: Frederick D. DiSanto, Cindy Schulze Flynn, Robert D. MacKinlay and Kimberly Smith Spacek. We urge stockholders to visit www.ABetterBlucora.com to read today’s letter and obtain important information about how to vote on the WHITE Proxy Card to elect our four-member slate. Mr. DiSanto, Ancora’s Chairman and Chief Executive Officer, commented: “Stockholders deserve a better Blucora after years of strategic missteps and significant value destruction under the current Board and Chief Executive Officer Chris Walters, who is also the Company’s longest-serving director. The Board – which lacks sufficient experience in the wealth management and tax advisory sectors – remains obstinately committed to a failed, six-year-old strategy that has not produced any meaningful synergies between Blucora’s Avantax and TaxAct businesses. This intransigence has persisted despite the Company’s botched acquisitions, bloated corporate cost structure, excessive debt and fraying relationships with advisors. We contend that the single biggest threat to Blucora’s long-term viability is its inexperienced, underqualified Board. This is why we tried to privately engage with the Company’s leadership this winter and sought to facilitate a credible, effective Board refresh that was in the best interest of stockholders. Unfortunately, Blucora validated our concerns about its broken corporate governance by refusing to negotiate in good faith and subsequently spending stockholder resources on high-priced external advisors tasked with trying to thwart our nominations. In our view, stockholders’ long-term interests will remain at risk as long as the incumbents continue to operate unchecked in Blucora’s boardroom. This is why we have nominated a diverse, well-rounded slate of director candidates, which is fully committed to bringing valuable financial services sector experience and independent perspectives to the Board. We believe the case for meaningful, stockholder-driven change atop Blucora is crystal clear.” *** Only by voting on the WHITE Proxy Card to elect all four of Ancora’s director candidates will stockholders be able to promptly install independent thinkers and industry experts on Blucora’s Board. Please visit www.ABetterBlucora.com to review our letter and learn how to vote on the WHITE Proxy Card. *** About Ancora Ancora Holdings, Inc. is an employee owned, Cleveland, Ohio based holding company which wholly owns four separate and distinct SEC Registered Investment Advisers and a broker dealer. Ancora Advisors LLC specializes in customized portfolio management for individual investors, high net worth investors, investment companies (mutual funds), and institutions such as pension/profit sharing plans, corporations, charitable & “Not-for Profit” organizations, and unions. Ancora Family Wealth Advisors, LLC is a leading, regional investment and wealth advisor managing assets on behalf families and high net-worth individuals. Ancora Alternatives LLC specializes in pooled investments (hedge funds/investment limited partnerships). Ancora Retirement Plan Advisors, Inc. specializes in providing non-discretionary investment guidance for small and midsize employer sponsored retirement plans. Inverness Securities, LLC is a FINRA registered Broker Dealer. Contacts For Investors: Ancora Alternatives LLC James Chadwick (216) 593-5048 firstname.lastname@example.org Saratoga Proxy Consulting LLC John Ferguson (212) 257-1311 Info@saratogaproxy.com For Media: Profile Greg Marose / Charlotte Kiaie, (347) 343-2999 email@example.com / firstname.lastname@example.org
MG Foods Recalls Various Turkey Sandwiches Due to Possible Listeria monocytogenes Contamination
CHARLOTTE, N.C.--(BUSINESS WIRE)--MG Foods of Charlotte, NC is recalling various Turkey Sandwiches due to a potential contamination of Listeria monocytogenes. Listeria monocytogenes is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, a Listeria monocytogenes infection can cause miscarriages and stillbirths among pregnant women. The products were distributed between March 3, 2021 and March 5, 2021 and packaged in clear plastic wedges & paper bags. The products were sold at distributors located at the Charlotte Douglas Airport and via vending machines and micro markets located in business locations in Georgia, North Carolina, South Carolina, and West Virginia. The company reacted swiftly and as of end-of-day March 5, 2021 affected products were removed from sale at all locations. No illnesses have been reported to date. On March 2, 2021 during routine environmental testing the company detected the presence of Listeria on surface areas where the recalled products were produced. Out of an abundance of caution, MG Foods is recalling the products due to the potential that some product may be contaminated with Listeria monocytogenes. Products recalled at the Charlotte Douglas Airport are: PRODUCT SIZE UPC CONTAINER USE BY DATES MG Foods Combo Half & Half 6.82 oz 1 00000 50069 9 Plastic Wedge 3/9/2021 MG Foods Turkey & Cheddar BLT 6.9 oz 1 00000 50068 2 Plastic Wedge 3/7/2021 MG Foods Turkey & Swiss Croissant 7.5 oz 1 00000 50011 8 Brown Bag 3/7/2021 Products recalled in vending machines and micro markets located in Georgia, North Carolina, South Carolina and West Virginia are: PRODUCT SIZE UPC CONTAINER USE BY DATES Fresh to You Club on Toast 10.3 oz MGF0930 Plastic Wrap 3/7/2021 Fresh to You Club Panini 8.50 oz MGF9844 Plastic Wrap 3/7/2021 Fresh to You Club Sub 9.14 oz C0932 Plastic Wrap 3/7/2021 Fresh to You Club Sub 9.14 oz MGF9100 Plastic Wrap 3/7/2021 Fresh to You Deluxe Triple Decker Club 12.17 oz MGF9719 Plastic Wrap 3/7/2021 Fresh to You Ham & Turkey Combo 5.85 oz MGF3054 Plastic Wedge 3/9/2021 Fresh to You Ham & Turkey Combo on 12 Grain 7.20 oz MGF6011 Plastic Wedge 3/9/2021 Fresh to You Jumbo Turkey & Cheese Sub 6.74 oz MGF1002 Plastic Wrap 3/9/2021 Fresh to You Market Club 11.85 oz MGF9800 Plastic Wrap 3/7/2021 Fresh to You Market Ham & Turkey Combo 5.85 oz MGF23054 Plastic Wrap 3/9/2021 Fresh to You Market Shaved Turkey & Cheese 4.55 oz MGF25571 Plastic Wedge 3/9/2021 Fresh to You Shaved Turkey & Cheese 4.55 oz MGF5571 Plastic Wedge 3/9/2021 Fresh to You Turkey & Baby Swiss on a Honey Brown Roll 9.42 oz MGF9703 Plastic Wrap 3/7/2021 Fresh to You Turkey & Cheddar Club 10.02 oz MGF9710 Plastic Wedge 3/7/2021 Fresh to You Turkey & Cheese Cut 6.56 oz MGF0596 Plastic Wedge 3/9/2021 Fresh to You Turkey & Cheese Hoagie 6.35 oz MGF0597 Plastic Wrap 3/9/2021 Fresh to You Turkey & Sun-Dried Tomato Aioli on Pita 8.29 oz MGF9806 Plastic Wrap 3/7/2021 Fresh to You Turkey & Swiss on a Kaiser Roll 8.1 oz MGF9712 Plastic Wrap 3/7/2021 Fresh to You Turkey & Swiss on a Wheat Roll 5.22 oz MGF0854 Plastic Wrap 3/9/2021 Fresh to You Turkey & Swiss on Whole Wheat 3.9 oz MGF0283 Plastic Wedge 3/9/2021 Fresh to You Turkey Club Croissant 7.94 oz MGF9103 Plastic Square 3/7/2021 Fresh to You Turkey Cranberry Pita 9.0 oz MGF9804 Plastic Wrap 3/7/2021 Fresh to You Turkey Melt Croissant 6.7 oz MGF3032 Plastic Wrap 3/9/2021 Fresh to You Tuscan Turkey Ciabatta 9.18 oz MGF9810 Plastic Wrap 3/7/2021 MG Foods Combo Half & Half 6.82 oz 1 00000 50069 9 Plastic Wedge 3/9/2021 MG Foods The Club Sub 8.5 oz 1 00000 50002 6 Brown Bag 3/9/2021 MG Foods Turkey & Cheddar BLT 6.9 oz 1 00000 50068 2 Plastic Wedge 3/7/2021 MG Foods Turkey & Pepperjack Sub 7.9 oz 1 00000 50055 2 Brown Bag 3/7/2021 MG Foods Turkey & Provolone BLT 8.1 oz 1 00000 50065 1 Plastic Wedge 3/7/2021 MG Foods Turkey & Provolone on 12 Grain 8.9 oz 1 00000 50066 8 Plastic Wedge 3/7/2021 MG Foods Turkey & Swiss Croissant 7.5 oz 1 00000 50011 8 Brown Bag 3/7/2021 Product labels are attached for identification of products. Consumers who have purchased these products are urged to discard any remaining product. Consumers may contact MG Foods at 1-855-424-8390 Monday thru Friday 7:00 am – 7:00 pm ET for any questions related to this recall or to request a full refund. Contacts Kristin Elder, Hill+Knowlton Strategies for MG FoodsKristin.Elder@hkstrategies.com
Review – All-New Range Rover Evoque (2019) D180 First Edition
In the SUV market highly popular around the world, Land Rover and Range Rover are considered the most iconic brands. Land Rover has been showing a special presence since SUV’s early concept esta...
Technical Overview of the 2nd Gen Xeon Scalable Processors
Intel hosted ‘Intel Data-Centric Press Workshop’ at Intel Jones Farm Campus in Hillsboro, Oregon, US on March 5 and 6, and introduced Intel's portfolio of solutions for the data-centric er...
Review - Encounter of Eun-hee Kim and Netflix, ‘Kingdom’ opened a new horizon
The master of drama genres, Eun-hee Kim, who had produced drama 'Sign', 'Signal', etc. unveils 'Kingdom' on Janua...
Review – [Jekyll and Hyde] Return of the King! There Is No Such Word as “Disappointment” in Seung Woo Jo, Jo-Jekyll’s Dictionary
It has been four years. It took a full four years for Seung Woo Jo to return to ‘Jekyll and Hyde’ as Jo-Jekyll. I can assure there wouldn’t have been any musical fans who did...
Review - Allm's Action Game 'CapsuleMon Fight', "A Game with Strategic confrontation of Capsule monsters" (mobile)
Allm, which has released popular games such as 'Lunia Z' and 'Kritika', is preparing various games to give new fun with mobile games, ‘CapsuleMon Fight’ will start service in early Novembe...
[CES 2021] LG Emphasized "Needs to Innovate Beyond Boundaries Between Fields in the New Normal Era" Through Future Talk
[CES 2021] Sony Unveiled Its Latest Initiatives Surpassing “Limits of Creativity” at CES 2021
Hyperconnect, Key to social platform success: reflecting the ‘user voice’
Hyperconnect : real-time video AI monitoring system can now auto-block live video content within 0.006 seconds
Explore Your Career Potential at the University of Nottingham Ningbo China
NINGBO, China--(BUSINESS WIRE)--At the University of Nottingham Ningbo China (UNNC), more than 2,000 students graduate each year with excellent academic qualifications and transferable skills. “Through combining innovative and interactive teaching pedagogies and world-class teaching facilities, UNNC will encourage you to think creatively, develop new ideas, and empower you with the necessary skills to become excellent global citizens,” says Professor May Tan-Mullins, Vice-Provost for Teaching and Learning. These are the future-proof skills and international gravitas that make UNNC graduates stand out to employers. UNNC graduates have secured jobs with prominent Chinese employers such as the Bank of China. On a global scale, alumni can be found excelling in leading multinational organisations such as Boeing, Amazon, Hilton, IKEA, KPMG, Nestlé, Standard Chartered Bank, DHL, Google, and more. UNNC’s high-quality British education is delivered at its campus in Ningbo, China. Lectures and seminars are held entirely in English, just as they are at the University of Nottingham UK. There are 29 undergraduate courses and 18 postgraduate taught courses to choose from, guided by academics who are, in many cases, world authorities in their fields. They are either seconded from Nottingham or appointed to the University of Nottingham’s standards. Research and learning materials are also imported from the UK and elsewhere. “UNNC is a great university to start the journey towards a professional career, not only because of its education but also because of all the advice and support given to students during their job hunting.” says Clara Martinez Naranjo, a Spanish student who majored in BA International Communications as an exchange student. Established in 2004, UNNC’s 144-acre campus is now home to over 8,000 students and where 60 countries and regions around the world are represented. Over 900 members of staff are split across academic and professional services, ensuring personalised support all around. To begin experiencing first-hand a student experience like no other in China, click here. Contacts University of Nottingham Ningbo China Chuchu Lou Content Manager Chuchu.email@example.com
NTT DATA Launches Platea Banking – A New Digital Banking Platform That Helps Banks Compose Innovative Open Banking Propositions
Platea Banking has been designed to empower banks and enable them to compete with fintechs and neobanks, by quickly launching new business models and differentiated services TOKYO--(BUSINESS WIRE)--#LATAM--NTT DATA, a recognised leader in consulting and IT services for the banking and financial services industry, today announced the launch of Platea Banking, a new digital banking platform. Platea Banking helps banks to address transformation challenges with their legacy technology, and to launch new services or innovative new business models faster. Banks are slowly adapting to modern banking, hindered by legacy systems and a lack of resources to create the digital experiences that consumers demand. As long-term partners to some of the world’s largest retail banks, NTT DATA has experienced these challenges for traditional banks first-hand and witnessed changes in the structure of banking created by the Open Banking era. As a result, Platea Banking has been built to help banks around the globe move away from monolithic models and enable them to create new operational models through a platform-based approach, which facilitates a more customer-centric focus to banking. Built with modern cloud-native banking architecture, Platea Banking is an open banking platform that brings an extensive integrated partner ecosystem and a set of functional modules that enables banks to build their own digital platforms. The modules include a full suite of services, from customer onboarding to lending, planning and financial management, card issuing and processing, and payments, among others. This cloud-focussed approach grants both elasticity and flexibility, so banks can use Platea Banking to grow their digital offering at a pace that suits them, without being locked into a specific vendor. Manuel Romero, Global Head of NTT DATA’s Open Banking Practice, commented: “Technology plays a central role in helping banks innovate and deliver next-generation banking services to their customers. With consumers demanding digital banking experiences, it is imperative that banks act accordingly to respond their needs. Platea Banking has been built to empower banks, providing them with a path to incorporate cloud-native technology to expand their business, as well as the ability to overcome obstacles such as scalability issues, legacy IT and compliance.” To find out more about Platea Banking and the services it provides, or to request for a demo of the platform, go to: https://www.plateabanking.com/ About Platea Banking Platea Banking is a trademarked open banking platform, built by NTT DATA Corporation. Platea Banking has been built using next-generation digital architecture to support the most challenging business ventures for banks and FSI businesses. It helps to transform legacy infrastructure through progressive core modernization, while simultaneously helping banks and FSI businesses launch new growth ventures through a greenfield technology stack. This helps them operate today and compete with new digital players, as well as set them up for success in future. Find out more about Platea Banking by visiting https://www.plateabanking.com/ Contacts NTT DATA Corporation, Global Marketing Headquarters Kaoru Kumashiro firstname.lastname@example.org
Asia Launches First Official Open Data Portal at Open Data Day 2021
TAIPEI, Taiwan--(BUSINESS WIRE)--#ODD2021--In conjunction with a data application workshop organized by Asia Open Data Partnership (AODP) at Open Data Day 2021, the current AODP secretariat, Taipei Computer Association announced the launch of Asia's first, official open data portal. Asia Open Data Portal offers a single point of access to open data published by institutions, agencies and organizations in a growing number of Asian member states, signaling a new era of data democratization across Asia. The portal currently features over 73.1 thousand datasets, organized into 20 catalogues and 12 categories, which can help to solve problems such as pollution in cities and the sourcing of PPE. Data is collected from a growing number of AODP member states, including South Korea, Japan, Taiwan, Philippines, Indonesia, Malaysia, Thailand and India. Challenges facing the project include the diversity of Asian languages and data formats used by the different states' public and private sectors, which AODP is overcoming with the use of machine translation and diplomatic efforts toward data standardization. The Asia Open Data Portal launch and data application workshop was live streamed on the DataEconomy.Taiwan YouTube channel, featuring talks from AODP representatives in Taiwan, Vietnam, Japan, India, Thailand and Cambodia. Special presentations were given by the 3 Invincible Award winners from last year's Asia Open Data Challenge. Firstly, a team member from GliaCloud (Taiwan) introduced her team’s AI video creation platform, GliaStar, which animates open data presentations with cartoon characters. Next, a team member from Smart Delivery (Japan) presented his team’s innovation in logistics, utilizing open data to incentivize and assist couriers in delivering food and medicine to elderly people in rural Japan. Lastly, a team member from Dbdbdeep (South Korea) explained how his team’s “Regional Social Turmoil Prediction Model” harnesses open data to identify the impacts of infectious diseases on society. AODP was established in 2015 with the primary aim of facilitating communication and cooperation on open data and data application between Asian countries. Asia Open Data Portal was initiated by Organization for Data-driven Application (Taiwan) in 2017, modeled on the EU Open Data Portal, and officially approved by the AODP member states in 2019. Its goal is to bolster Asia’s industrial development across all sectors and emerging technologies, such as AI and IoT. Contacts Press: Daniel Cunningham, email@example.com +886 223117007
Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia
– The REMDACTA clinical trial of Actemra plus Veklury did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone – – Genentech will submit the REMDACTA results to a peer-reviewed journal – SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the global Phase III randomized, double-blind, multicenter REMDACTA study of Actemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc. Genentech will continue to evaluate data from the REMDACTA, COVACTA and EMPACTA studies as well as other studies of Actemra in COVID-19 pneumonia. The EMPACTA study met its primary endpoint, while COVACTA did not meet its primary endpoint. Both were recently published in the New England Journal of Medicine. “Given the global impact of COVID-19 pneumonia on patients, we are disappointed that the REMDACTA study did not meet its endpoints,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We continue to believe that the totality of data suggests a potential role for Actemra in treating certain patients with COVID-19, and will discuss the results with health authorities. We thank our partners at Gilead, and all the patients, investigators and healthcare professionals for their participation.” REMDACTA did not meet key secondary endpoints, which included likelihood of death, likelihood of progression to mechanical ventilation or death, and clinical status. The full results of the trial will be submitted for publication in a peer-reviewed journal later this year. Actemra is not approved for the treatment of COVID-19 pneumonia. The antiviral medication Veklury was invented and developed by Gilead Sciences and is approved by the U.S. Food and Drug Administration for the treatment of adults and pediatric patients at least 12 years of age and weighing at least 40 kilograms requiring hospitalization for COVID-19. Veklury is contraindicated in patients who are allergic to Veklury or any of its components. For more information, please see the U.S. full Prescribing Information at https://www.gilead.com. For more information on how Genentech is responding to the global COVID-19 pandemic, please visit our COVID-19 response page. About the REMDACTA Trial REMDACTA is a two-armed global Phase III, randomized, double-blind, multicenter study (REMDACTA, NCT04409262) to evaluate the efficacy and safety of Actemra plus Veklury, versus placebo plus Veklury in hospitalized patients with severe COVID-19 pneumonia receiving standard of care. Veklury is an antiviral medicine that works to stop replication of SARS-CoV-2, the virus that causes COVID-19. The REMDACTA trial is being conducted in collaboration with Gilead Sciences, Inc. The primary endpoint of the study is improvement in time to hospital discharge by day 28. Key secondary endpoints include likelihood of death, likelihood of progression to mechanical ventilation or death, and clinical status. Clinical status is measured by the 7-category ordinal scale, which tracks patients’ clinical status based on the need for intensive care and/or ventilator use, as well as supplemental oxygen requirements. Patients will be followed for 60 days post-randomization. About the COVACTA Trial COVACTA is a global, randomized, double-blind, placebo-controlled Phase III study (COVACTA, NCT04320615) which evaluated the safety and efficacy of intravenous Actemra added to standard of care in adult patients hospitalized with severe COVID-19 pneumonia compared to placebo plus standard of care. The primary and secondary endpoints included clinical status, mortality, mechanical ventilation and intensive care unit (ICU) variables. Patients were followed for 60 days post-randomization. About the EMPACTA Trial EMPACTA (Evaluating Minority Patients with Actemra) is a Phase III, randomized, double-blind, placebo-controlled multicenter study (EMPACTA, NCT04372186) which evaluated the efficacy and safety of Actemra in the treatment of hospitalized COVID-19 pneumonia among patients that are often underrepresented in clinical trials. The primary endpoint was the cumulative proportion of participants dying or requiring mechanical ventilation by day 28. Secondary endpoints included: time to clinical failure, defined as the time to death, mechanical ventilation, ICU admission, or withdrawal (whichever occurs first); mortality rate by day 28; and time to hospital discharge or “ready for discharge.” About Actemra Actemra was the first humanized interleukin-6 (IL-6) receptor antagonist approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have used one or more disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), that did not provide enough relief. The extensive Actemra RA IV clinical development program included five Phase III clinical studies and enrolled more than 4,000 people with RA in 41 countries. The Actemra RA subcutaneous clinical development program included two Phase III clinical studies and enrolled more than 1,800 people with RA in 33 countries. Actemra subcutaneous injection is also approved for the treatment of adult patients with giant cell arteritis (GCA), for the treatment of patients two years of age and older with active polyarticular juvenile idiopathic arthritis (PJIA) or active systemic juvenile idiopathic arthritis (SJIA), and for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). In addition, Actemra is also approved in the IV formulation for patients two years of age and older with active PJIA, SJIA or CAR T cell-induced cytokine release syndrome (CRS). Actemra is not approved for subcutaneous use in people with CRS. It is not known if Actemra is safe and effective in children with PJIA, SJIA or CRS under two years of age or in children with conditions other than PJIA, SJIA or CRS. Actemra is intended for use under the guidance of a healthcare practitioner. Important Safety Information Actemra can cause serious side effects. Actemra changes the way a patient’s immune system works. This can make a patient more likely to get infections or make any current infection worse. Some people taking Actemra have died from these infections. Actemra can cause other serious side effects. These include: Tears of the stomach or intestines Liver problems (hepatotoxicity) Changes in blood test results, including low neutrophil (white blood cells) and platelet (platelets help the blood to clot) counts, and increases in certain liver function test levels and blood cholesterol levels An increased risk of certain cancers by changing the way a patient’s immune system works Hepatitis B infection Serious allergic reactions, including death. These may happen with Actemra infusions or injections, even if they did not occur with an earlier infusion or injection. If a patient has had hives, a rash, or experienced flushing after injecting, the patient should tell their doctor or nurse before their next injection Nervous system problems Patients should not receive Actemra if they are allergic to Actemra or if they have had a bad reaction to Actemra previously. Most common side effects in patients treated with Actemra: Patients should tell their doctor if they have these or any other side effect that bothers them or does not go away: Upper respiratory tract infections (like common cold and sinus infections) Headache Increased blood pressure (also called hypertension) Injection site reactions Actemra & pregnancy: Patients should tell their doctor if they are planning to become pregnant, are pregnant, plan to breastfeed, or are breastfeeding. The patient and their doctor should decide if the patient will take Actemra or breastfeed. Patients should not do both. If a patient is pregnant and taking Actemra, they should join the pregnancy registry. To learn more, patients should call 1-877-311-8972 or talk to their doctor to register. Patients should tell their doctor right away if they are experiencing any side effects. Report side effects to the FDA at 1-800-FDA-1088 or http://www.FDA.gov/medwatch. Report side effects to Genentech at 1-888-835-2555. Please visit http://www.actemra.com for the full Prescribing Information, including Boxed Warning and Medication Guide, for additional Important Safety Information or call 1-800-ACTEMRA (228-3672). About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com. Contacts Media Contact: Shirley Dang (650) 467-6800 Advocacy Contact: Bill Caddell (704) 774-2611 Investor Contacts: Loren Kalm (650) 225-3217 Karl Mahler 011 41 61 687 8503
Toyoda Gosei Receives Toyota’s Technology & Development Award for Development of High Pressure Hydrogen Tanks
Contribution to extension of FCVs’ cruising range KIYOSU, Japan--(BUSINESS WIRE)--Toyoda Gosei Co., Ltd. (TOKYO: 7282) received the Technology & Development Award from Toyota Motor Corporation for the development of high pressure hydrogen tanks used on the new MIRAI, launched by Toyota in December 2020. High pressure hydrogen tanks are a crucial component for fuel cell vehicles (FCVs), which efficiently hold hydrogen compressed at high pressure (about 700 atm). The new MIRAI is equipped with three hydrogen tanks, one more than the previous model, to extend its cruising range. This is an issue that is important for the widespread adoption of FCVs. Toyoda Gosei produces the third high pressure hydrogen tank*, which is located in the rear of the new MIRAI, while Toyota continues to produce the other two. Toyoda Gosei developed the new tank together with Toyota Motor Corporation. For the new tanks, improvements have been made in the materials used in the carbon fiber reinforced plastic layer, one of the three layers of the tank wall (layer to withstand high pressure), production methods and other factors. As a result, the hydrogen storage efficiency of the tank, which is the ratio of the mass of stored hydrogen to the mass of the tank, was increased about 10 percent by minimizing the wall thickness to increase the inner volume while maintaining the pressure resistance strength. Toyoda Gosei will continue to develop products leveraging its core technologies of rubber and plastic with the aim of supporting the spread of electrified vehicles such as electric vehicles (EVs) and FCVs. * The production started from November 2020 at the Inabe Plant (Inabe, Mie prefecture, Japan) which was established as a dedicated plant for high pressure hydrogen tanks. Contacts Toyoda Gosei Co., Ltd.Contact: Takatomo Abe firstname.lastname@example.org